Thus, the finding that PTEN methylation/mutation is highly specific to and frequent in the E1/E2 tumours indicates that PTEN may serve as a diagnostic marker to identify those patients for which inhibition of the FGFR4/PI3K/AKT axis could have a key therapeutic role. The gene discussed is AKT1; the disease is neoplasm.